Sorry, you need to enable JavaScript to visit this website.

Weight Gain Factors and Considerations | SYMTUZA® (darunavir/cobicistat/emtricitabine/tenofovir alafenamide) HCP

Patients at Risk: Weight

What Patient Factors Weigh Into Your ARV Choice?

Patient silhouette

ARV-RELATED WEIGHT CONSIDERATIONS

Clinical:

  • High-risk demographics
  • Overweight/obese (BMI ≥25)
  • Family history of obesity, T2D, or hypertension

Lifestyle/Attitude:

  • Concerned about ARV-related weight gain
  • Unsuccessful with diet and exercise

 

 

ARV=antiretroviral; BMI=body mass index; T2D=type 2 diabetes.

Reference: Department of Health and Human Services. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. Updated January 20, 2022. Accessed March 8, 2022. https://clinicalinfo.hiv.gov/en/guidelines/adult-and-adolescent-arv/whats-new-guidelines

You may be interested in: